Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...

Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...

We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...

The U.K. will recognize a Palestinian state if there’s no cease-fire. Britain’s prime minister, Keir Starmer, announced ...

Shares of Hims & Hers, which has clashed with Novo Nordisk over its sales of compounded glucagon-like peptide inhibitors, rose slightly in the wake of the report, and have more than doubled in value ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...